260 related articles for article (PubMed ID: 24281561)
1. Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.
Chiba K; Adachi K
Pharmaceuticals (Basel); 2012 May; 5(5):514-28. PubMed ID: 24281561
[TBL] [Abstract][Full Text] [Related]
2. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
3. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
4. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
5. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
[TBL] [Abstract][Full Text] [Related]
6. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
8. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
9. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
Matloubian M; Lo CG; Cinamon G; Lesneski MJ; Xu Y; Brinkmann V; Allende ML; Proia RL; Cyster JG
Nature; 2004 Jan; 427(6972):355-60. PubMed ID: 14737169
[TBL] [Abstract][Full Text] [Related]
11. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
Samuvel DJ; Saxena N; Dhindsa JS; Singh AK; Gill GS; Grobelny DW; Singh I
PLoS One; 2015; 10(10):e0141781. PubMed ID: 26513477
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
13. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Oo ML; Thangada S; Wu MT; Liu CH; Macdonald TL; Lynch KR; Lin CY; Hla T
J Biol Chem; 2007 Mar; 282(12):9082-9. PubMed ID: 17237497
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis.
Sic H; Kraus H; Madl J; Flittner KA; von Münchow AL; Pieper K; Rizzi M; Kienzler AK; Ayata K; Rauer S; Kleuser B; Salzer U; Burger M; Zirlik K; Lougaris V; Plebani A; Römer W; Loeffler C; Scaramuzza S; Villa A; Noguchi E; Grimbacher B; Eibel H
J Allergy Clin Immunol; 2014 Aug; 134(2):420-8. PubMed ID: 24679343
[TBL] [Abstract][Full Text] [Related]
17. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
[TBL] [Abstract][Full Text] [Related]
18. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
[TBL] [Abstract][Full Text] [Related]
20. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
